Source: Barrett, et al JAMA Surgery, September 17, 2025 Researchers correlated insurance claims data and electronic medical records in a system that owns both an insurance plan (Highmark) and a provider system (Allegheny Health), and compared total medical expense for over 30,000 individuals who had either metabolic and bariatric surgery (sleeve gastrectomy) or were treated with GLP-1 medications between 2018 and 2023
However, patients receiving GLP-1-RAs had also been treated longer, which could have affected the likelihood of reducing the medication for IIH
This pattern is not unique to GLP-1 therapy
Over 100 million Americans watched Hims & Hers (HIMS) controversial Super Bowl ad taking on the weight-loss drug industry this Sunday during the Super Bowl.
If side effects are troublesome, your provider may adjust your dose gradually rather than skip doses entirely
Microglia dictate the impact of saturated fat consumption on hypothalamic inflammation and neuronal function